This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
by Zacks Equity Research
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi
by Zacks Equity Research
The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
The Zacks Analyst Blog Highlights NVIDIA, Johnson & Johnson, T-Mobile US and The Eastern
by Zacks Equity Research
NVIDIA, Johnson & Johnson, T-Mobile US and The Eastern are included in this Analyst Blog.
Top Research Reports for NVIDIA, Johnson & Johnson and T-Mobile
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Johnson & Johnson (JNJ) and T-Mobile US, Inc. (TMUS), as well as a micro-cap stock The Eastern Company (EML).
AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs
by Zacks Equity Research
ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
by Zacks Equity Research
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's overall clinical program data.
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?
by Sundeep Ganoria
Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.
Is ISRG a Buy After Logging Robust System Placements in Q4?
by Indrajit Bandyopadhyay
Intuitive Surgical has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. The stock has also gained during the past month. Let's see if the trend might change.
How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance
by Kinjel Shah
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
by Kinjel Shah
J&J announces Q4 earnings. FDA approves AZN and Daiichi's Dato-DXd for breast cancer.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma
by Zacks Equity Research
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
Zacks Earnings Trends Highlights: Netflix and Johnson & Johnson
by Zacks Equity Research
Netflix and Johnson & Johnson have been highlighted in this Earnings Trends article.
Earnings Picture Remains Strong: A Closer Look
by Sheraz Mian
The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the coming quarters.